1200 G Street NW, Suite 400 Washington, DC 20005-3814

Tel: 202 783 8700 Fax: 202 783 8750 www.AdvaMed.org

3068 '01 DEC 19 P4:22



December 18, 2001

Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1060 Rockville, MD 20852

Re: Docket No. OOD-15381: Draft Guidance for Industry; Electronic Records;

Electronic Signatures, Validation; Availability


Dear Sir or Madam:

I am writing on behalf of the AdvaMed Part 11 Issue Working Group, which represents a cross-section of our member companies affected by the rule. AdvaMed, the Advanced Medical Technology Association, (formerly the Health Industry Manufacturers Association) represents more than 800 innovators and manufacturers of medical devices, diagnostic products and medical information systems. Our members produce nearly 90 percent of the \$68 billion health care technology products consumed annually in the United States, and nearly 50 percent of \$159 billion purchased around the world annually.

We have reviewed the subject document in detail and have developed a number of comments, both general and specific. The general comments are addressed below, and the specific comments are contained in the attached table.

#### **General Comments**

Much of this document repeats information contained in the draft *Guidance for Industry:* General Principles Of Software Validation, which is intended to explain the requirements for validation of software contained in medical devices, the software used for the manufacture of medical devices, and the software used in medical manufacturing quality systems. Our understanding is that the current document is intended to address those aspects of software validation that are peculiarly relevant to Part 11 requirements. We believe that this document needs significant editing to limit it to that subject. It will not benefit either the industry or the agency to have two documents that address general





aspects of software validation in slightly different ways. This document needs to be carefully focused.

We also believe that the Agency has paid too little attention to validation of hybrid systems. It is clear that many hybrid systems currently exist and will continue to exist for the foreseeable future. If FDA expects these systems to be validated for compliance with Part 11, then the guidance should address such validation.

We hope that our comments prove useful. Please contact me with any questions regarding these comments.

Sincerely,

Bernie Liebler Director

Technology and Regulatory Affairs

#### AdvaMed Comments - Draft Guidance on Part 11 Validation

Comment er	Section	Line No.	Proposed Change	Date 12/19/2001 Com	Document Part 11 Validation Draft Guidance ment/ Rationale
Advamed	3	39	Delete the word "all," and add definitions for those terms pertinent to the guidance and not contained in the cited document.	Clarification. The word "all" contain all of the definitions u	adds no meaning. This section should useful in understanding the guidance.
Advamed	4	46	Modify sentence from: " satisfy this requirement persons" to "satisfy this and other Part 11 requirements, persons"	As it is currently stated this document would be restricted to only validation requirements stated in Section 11.10.	
Advamed	5	49	Change sentence to read "when validating electronic computer systems."	The use of the term "record keeping" is ambiguous. There are computer systems that maintain records, but also perform other functions. Describing them as "electronic record keeping computer systems" is inaccurate. FDA may want to consider recasting as "electronic computer systems that contain electronic records as defined in Part 11" or something similar.	
Advamed	5.1	54	Modify sentence: "Without first establishing end user needs" to "without establishing end user needs" Delete the word "first"	Computer system development is an iterative process in which user requirements are identified and modified. Having the statement read 'Without <u>first</u> establishing' appears to indicate that the requirements are developed and never changed.	
Advamed	3	56	Delete the phrase "and intended uses"	Intended uses are a subset of "intended use" is included, a	of the user requirements. If the phrase definition would be needed for "intended stronic records system (as contrasted
Advamed	5.1	61	After "confidentiality." Add, "Validations performed by OTS vendors can only confirm conformance to their general requirements. End users need to show that the system meets end user intended requirements."	It is important to recognized that while the vendor may perform a very complete validation the end user still must confirm that their "intended uses" are fulfilled.	
Advamed	5.1	61 thru 70	Remove all starting with sentence "For example"	There is no need to restate the requirement from Part 11. The need to include predicate rule requirements as well as Part 11 requirements are adequately stated above and this adds no value.	
Advamed	5.2	84	Replace the first sentence with the following: It is critical that any validation be documented.	Although the content of this section moves beyond what is needed specifically for validation for Part 11 compliance, it is worth noting the critical nature of documentation, as undocumented validation is equivalent to no validation at all.	
Advamed	5.2.2	95	Add,as well as test methods or test cases and	Providing test cases to be used should in some cases be sufficient.	

Comment er	Section	Line No.	Proposed Change	Date 12/19/2001 Part 11 Validation Draft Guidance Comment/ Rationale		
Advamed	5.2.3	100-101	test results should beterms. For non- quantifiable observations, "pass/fail" results are acceptable.	Pass/Fail is a legitimate app	olication of non-quantifiable observations.	
Advamed	5.3	103-106	Delete this section	This is beyond the scope of this Guidance Document. Also, the text refers to both hardware and software. Once again, not limited to Part 11.		
Advamed	3	New	Add the Coalition remarks differentiating between Data Records and Document Records.	Requirements for these two record types differ significantly.  Furthermore the various FDA centers differ in the requirements contained in their predicate rules concerning these record types.  Finally the approaches to appropriate validation vary depending on the record type.		
Advamed	5.3	106	Add to end of paragraph: "Procedures used during installation and tests run should be documented."	User should be able to exactly reproduce conditions during installation.		
Advamed	5.4	109	Change paragraph to read "Test conditions: test conditions should include not only "normal" or "expected" values but also extended boundary values, unexpected data entries, error conditions, reasonableness challenges (e.g. empty fields and data outliers), branches, data flow and combinations of inputs. Testing should also include stress conditions (such as a high number of users accessing the system at the same time).	Information flow seems mor	re connected with this variation of the text.	
Advamed	5.4.1	115 and 116	Change "Live, user-site tests: these tests are performed in the end user's computing environment under actual operating conditions." to "User Acceptance and System Performance Qualification tests: these tests are performed under anticipated operating conditions that duplicate the intended end user computing environment."	Need to indicate that testing may not necessarily be conducted directly in the actual production environment due to the sensitivity of data/records created in order to "demonstrate" the system prior to system certification and launch. If the intent was to indicate that routine user surveillance of operating characteristics is required after commissioning the system, then this was not clear. Normally, system performance ("Validation Testing", or "Performance Qualification") testing is not conducted in the live environment before the system has been certified. These tests are crucial to the evaluation of system performance as a part of the certification approval process.		
Advamed	5.4.1	116	AddWhen possible, testing should cover	It is almost impossible for some end users (e.g., a blood testing center) to do this under continuous operations when some of them are still testing around the clock.		

Comment er	Section	Line No.	Proposed Change	Date 12/19/2001 Com	Document Part 11 Validation Draft Guidance ment/ Rationale
Advamed	5.4	116	After "conditions." Add, "System test in user environment should duplicate operating conditions but the software must not be used in manufacturing or to support manufacturing until validation is complete and system is shown to meet the requirements."	Emphasize that this is prior to use in production to support quality system. Using an un-validated system would result in a violation of GMPs, cGMPs etc.	
Advamed	5.4.2	127	Add to end of paragraph: "Structural Testing is normally performed by the software developers."	Users of COTS software cannot perform structural testing.	
Advamed	5.4.2	133	Add sentence outside bullets "The level of effort should be commensurate with the level of complexity of the system being validated"	It is important to understand that simple software will not require as much testing as more complex systems. The overall validation approach should define this before the design and testing are started. See "Draft Guidance for Industry General Principles of Software Validation" part IV section "H".	
Advamed	5.4.3	135-137	Delete: "rather than qualified (e.g., pass/fail)" Add to end of paragraph "For non quantifiable observations, "pass/fail" results are acceptable."	Pass/Fail is a legitimate appl	lication of non-quantifiable observations.
Advamed	5.5	138-146	Delete this section	the text to the " General Pi	sinterpretation issues when comparing rinciples of Software Validation" onsiderations are restrictive and would re that should be considered.
Advamed	5.5	143	After "reviews." Add, "The use of a systematic approach to software design, development and implementation, as expressed in the definition of a life cycle model, provides a framework to ensure the proper integration of these concepts. Testing alone will not ensure error free software but following a defined methodology provides the best chance of minimal correctable errors."		nodel is an accepted, proven method for neet the user needs with a minimum of
Advamed	5.7	158	Change validation to testing	The process of validation includes all aspects including the activities of the developers. Validation encompasses the life cycle and therefore must include the developers. Testing, however, should be performed by persons not directly involved in the development of the code to be tested. Testing is what should be independent	
Advamed	5.8	167	Add to end of line "and require re-validation"	Emphasize the need to re-validate to ensure the integrity of the modified system.	
Advamed	5.8	167	Add examples of significant changes.	Clarification	

Comment er	Section	Line No.	Proposed Change	Date 12/19/2001	Document Part 11 Validation Draft Guidance comment/ Rationale	
Advamed	5.8	170 - 176	In line 170 after "system." Insert sentences from line 173 starting with "It is important" through sentence ending with "appropriate revalidation."	Clarify the importance of review and planned revalidation.		
Advamed	6.1.1	196	After " specifications." Add, "Typically, for custom designed software, the developers requirement specifications will differ from the end users requirements. Review, by the user, of the user requirements and the matching development requirements should be done. This activity typically cannot be performed for off the shelf software. Additional measures should be taken.	While this activity is important it will not always be possible for OTS software. However the following section provides the tools to evaluate OTS software. This change clarifies the roles for custom and OTS development.		
Advamed	6.1.1	196	Strike the sentence: "If possible the end user should obtain a copy of the developer's requirement's specification for comparison."	The end user's specifications are specific to their requirements. The developer's specification is not relevant, and attempting to compare them will only add complexity and non-value added labor to the process.		
Advamed	6.1.2	199 -208		The requirements under 6.1.2 (software structural integrity) are too stringent for the majority of the requirements. Validation of the end users use of the software should be deemed sufficient for these applications. The requirement in 6.1.2 should apply only to very few systems where a high degree of risk that the system poses to product safety, efficacy, and quality.		
Advamed	6.1.2	200	Change "doing" to "documenting" and remove "all of the following " and replace it with "the activities performed to ensure the adequacy of the software structural integrity, such as:"	If the activities are to be done they should be documented. This would be FDA's expectation, so we should state that. It will not be possible to do all of the stated activities, as some vendors may not provide audit opportunity (e.g. Microsoft). Analysis of the risk vs. the use of the software should determine the level of validation activities performed.		
Advamed	6.1.2	203	Delete section (3)	This data is probably not involve confidentiality iss	forthcoming from vendors, and would sues beyond the usual scope of validation.	
Advamed	6.1.2	204	Remove "and"	See comments for line 20		
Advamed	6.1.3	210	Replace sentence starting with "End users should" with "End users should perform testing of the system in sufficient detail to verify user requirements have been met."	There should be a linking of the requirements to the testing. One of the primary premises of validation is to ensure requirements are met and one of the tools is proper testing.		
Advamed		217	Delete the last sentence of this paragraph: "Note, however, we do not establish software adequacy."	This duplicative information is redundant and already stated in the previous section (6.1.2). Restating this information differently can lead to misinterpretation and misunderstanding.		
Advamed	6.2.1	223	Add "a" between "as" and "computer"	Typo error		

Comment er	Section	Line No.	Proposed Change	Date 12/19/2001	Document Part 11 Validation Draft Guidance mment/ Rationale
Advamed	6.2.1- Internet Validation	234-239	Delete this sentence: "Examples of such measures include:  • Use of digital is affirmed. • Delivery acknowledgements telephone lines.)"	These examples are too restrictive since other options exist. Stating these examples leads to focus on this specific example as requirements to the detriment of other options.  The delivery acknowledges utilizing fax or voice telephone are logistically very inefficient and very ineffective for dynamic, high volume systems.  Finally, the intent of such acknowledgements is unclear and ambiguous. We strongly recommend a separate guidance for dynamic web pages, e-mail, and the internet.	
Advamed	Appendix A References	NA	General comments related to Appendix A - References: This is an exhaustive list of references that are too numerous for practical use. There are obvious inconsistencies in the stated requirements when comparing the content in all of the listed references. We strongly recommend that the list include only those references that are used to develop this Guidance Document and which state consistent requirements and interpretations.		with wording which describes the

# Guidance for Industry

## 21 CFR Part 11; Electronic

# **Records; Electronic Signatures**

### **Validation**

#### **Draft Guidance**

#### This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit comments to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, room 1061, Rockville, MD 20852. All comments should be identified with the docket number OOD-1538.

For questions regarding this draft document contact Paul J. Motise, Office of Enforcement, Office of Regulatory Affairs, 301-827-0383, e-mail: pmotise@ora.fda.gov.

U.S. Department of Health and Human Services
Food and Drug Administration
Office of Regulatory Affairs (ORA)
Center for Biologics Evaluation and Research (CBER)
Center for Drug Evaluation and Research (CDER)
Center for Devices and Radiological Health (CDRH)
Center for Food Safety and Applied Nutrition (CFSAN)
Center for Veterinary Medicine (CVM)
August 2001

# Guidance For Industry 21 CFR Part 11; Electronic Records; Electronic Signatures Validation

Additional copies of this draft guidance document are available from the Office of Enforcement, HFC-200, 5600 Fishers Lane, Rockville, MD 20857; Internet http://www.fda.gov/ora/compliance ref/partl1.htm

U.S. Department of Health and Human Services
Food and Drug Administration
Office of Regulatory Affairs (ORA)
Center for Biologics Evaluation and Research (CBER)
Center for Drug Evaluation and Research (CDER)
Center for Devices and Radiological Health (CDRH)
Center for Food Safety and Applied Nutrition (CFSAN)
Center for Veterinary Medicine (CVM)
August 2001

#### **Guidance For Industry**

#### 21 CFR Part 11; Electronic Records; Electronic Signatures

#### **Validation**

#### **Table of Contents**

1. Purpose	1
2. Scope	1
2.1 Applicability	2
2.2 Audience	3
3. Definitions and Terminology	3
4. Regulatory Requirements; What Does Part 11 Require?	3
5. Key Principles	4
5.1 System Requirements Specifications	4
5.2 Documentation of Validation Activity	6
5.2.1 Validation Plan	6
5.2.2 Validation Procedures	6
5.2.3 Validation Report	6
5.3 Equipment Installation	7
5.4 Dynamic Testing	7
5.4.1 Key Testing Considerations	7
5.4.2 Software testing should include:	8
5.4.3 How test results should be expressed.	8
5.5 Static Verification Techniques	9
5.6 Extent of Validation	9
5.7 Independence of Review	10
5.8 Change Control (Configuration Management)	10
6. Special Considerations	
6.1 Commercial, Off-The-Shelf Software	11
6.1.1 End User Requirements Specifications	12
6.1.2 Software Structural Integrity	12
6.1.3 Functional Testing of Software	
6.2 The Internet	
6.2.1 Internet Validation	13
Appendix A - References	.15

#### **Guidance For Industry**<sup>1</sup>

# 21 CFR Part 11; Electronic Records; Electronic Signatures Validation

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of applicable statutes and regulations.

#### 1. Purpose

- 1 The purpose of this draft guidance is to describe the Food and Drug Administration's
- 2 (FDA's) current thinking regarding considerations in meeting the validation requirements of
- 3 Part 11 of Title 21 of the Code of Federal Regulations; Electronic Records; Electronic
- 4 Signatures. It provides guidance to industry, and is intended to assist persons who are
- 5 subject to the rule to comply with the regulation. It may also assist FDA staff who apply
- 6 part 11 to persons who are subject to the regulation.

#### 2. Scope

9

- 7 This draft guidance is one of a series of guidances about part 11. We intend to provide
- 8 information with respect to FDA's current thinking on acceptable ways of meeting part 11

This draft guidance was prepared under the aegis of the Office of Enforcement by the FDA Part 11

<sup>10</sup> Compliance Committee. The committee is composed of representatives from each center within the Food

<sup>11</sup> and Drug Administration, the Office of Chief Counsel and the Office of Regulatory Affairs.

- requirements to ensure that electronic records and electronic signatures are trustworthy,
- reliable, and compatible with FDA's public health responsibilities.
- 14 Electronic record and electronic signature systems consist of both manual procedural
- 15 controls and technical controls implemented through computer systems. This draft
- 16 guidance focuses on validation of computer systems. It identifies key validation principles
- and addresses some frequently asked questions, but it is not intended to cover everything
- 18 that computer systems validation should encompass in the context of electronic
- 19 record/electronic signature systems. You can read more information about computer
- 20 systems validation in the documents listed in Appendix A References.

#### 2.1 Applicability

- 21 This draft guidance applies to electronic records and electronic signatures that persons
- 22 create, modify, maintain, archive, retrieve, or transmit under any records or signature
- 23 requirement set forth in the Federal Food, Drug, and Cosmetic Act (the Act), the Public
- 24 Health Service Act (PHS Act), or any FDA regulation. Any requirements set forth in the
- 25 Act, the PHS Act, or any FDA regulation, with the exception of part 11, are referred to in
- this document as predicate rules. Most predicate rules are contained in Title 21 of the
- 27 Code of Federal Regulations. In general, predicate rules address the research, production.
- 28 and control of FDA regulated articles, and fall into several broad categories. Examples of
- 29 such categories include, but are not limited to, manufacturing practices, laboratory

- 30 practices, clinical and pre-clinical research, adverse event reporting, product tracking, and pre-
- 31 and post marketing submissions and reports.

#### 2.2 Audience

- We intend this draft guidance to provide useful information and recommendations to:
- Persons subject to part 11;
- Persons responsible for validation of systems used in electronic recordkeeping;
- Persons who develop products or services to enable implementation of part 11
   requirements; and,
- This draft guidance may also assist FDA staff who apply part 11 to persons subject to the regulation.

#### 3. Definitions and Terminology

- Unless otherwise specified below, all terms used in this draft guidance are defined in FDA's
- draft guidance document, "Guidance For Industry, 21 CFR Part 11; Electronic Records;
- 41 Electronic Signatures, Glossary of Terms," a document common to the series of guidances
- 42 on part 11.

#### 4. Regulatory Requirements; What Does Part 11 Require?

- 43 Section 11.10 requires persons to "employ procedures and controls designed to ensure the
- 44 authenticity, integrity, and, when appropriate, the confidentiality of electronic records, and to
- 45 ensure that the signer cannot readily repudiate the signed record as not genuine." To

- satisfy this requirement persons must, among other things, employ procedures and controls
- 47 that include "[v]alidation of systems to ensure accuracy, reliability, consistent intended
- 48 performance, and the ability to discern invalid or altered records."

#### 5. Key Principles

- 49 Here are some key principles you should consider when validating electronic recordkeeping
- 50 computer systems.

#### 5.1 System Requirements Specifications

Regardless of whether the computer system is developed in-house, developed by a contractor, or purchased off-the-shelf, establishing documented end user (i.e., a person regulated by FDA) requirements is extremely important for computer systems validation. Without first establishing end user needs and intended uses, we believe it is virtually impossible to confirm that the system can consistently meet them. Once you have established the end user's needs and intended uses, you should obtain evidence that the computer system implements those needs correctly and that they are traceable to system design requirements and specifications. It is important that your end user requirements specifications take into account predicate rules, part 11, and other needs unique to your system that relate to ensuring record authenticity, integrity, signer non-repudiation, and, when appropriate, confidentiality. For example, as noted above, section 11.10 has a general requirement that persons who use closed systems to create, modify, maintain, or transmit electronic records must employ procedures and controls designed to ensure the

authenticity, integrity, and, when appropriate, the confidentiality of electronic records, and to ensure that signers cannot readily repudiate signed records as not genuine. In addition, section 11.30 requires persons who use open systems to employ procedures and controls identified in section 11.10, as appropriate; persons who use open systems must also implement special procedures and controls, such as document encryption and use of digital signature standards, as necessary under the circumstances, to ensure record authenticity, integrity, and confidentiality.

- Other factors not specifically addressed in part 11 may also impact on electronic record trustworthiness, integrity and system performance. You should consider these factors and establish appropriate requirements specifications for them, as well. Here are some examples:
  - Scanning processes: where a paper record is scanned to create an electronic record, scanner resolution, scanning rates, color fidelity, and the type of hardware interface may impact the accuracy and reliability of the electronic record as well as system performance.
  - Scalability: in a networked environment, system performance may be affected by the number of workstations and bandwidth demands of file size and types.
  - Operating environment: sources of electromagnetic interference, radio frequency interference, temperature/humidity, and electrical power fluctuations may affect system performance.

#### 5.2 Documentation of Validation Activity

- We consider thorough documentation to be extremely important to the success of your
  validation efforts. Validation documentation should include a validation plan, validation
  procedures, and a validation report, and should identify who in management is responsible for
- approval of the plan, the procedures and the report.
- 88 5.2.1 Validation Plan
- The validation plan is a strategic document that should state what is to be done, the scope
- of approach, the schedule of validation activities, and tasks to be performed. The plan
- should also state who is responsible for performing each validation activity. The plan
- 92 should be reviewed and approved by designated management.
- 93 5.2.2 Validation Procedures
- 94 The validation procedures should include detailed steps for how to conduct the validation.
- 95 It should describe the computer system configuration, as well as test methods and
- 96 objective acceptance criteria, including expected outcomes. The procedures should be
- 97 reviewed and approved by designated management.
- 98 5.2.3 Validation Report
- 99 The validation report should document detailed results of the validation effort, including test
- 100 results. Whenever possible, test results should be expressed in quantified terms rather
- than stated as "pass/fail." The report should be reviewed and approved by designated
- 102 management.

#### 5.3 Equipment Installation

Prior to testing, you should confirm that all hardware and software are properly installed and, where necessary, adjusted and calibrated to meet specifications. User manuals, standard operating procedures, equipment lists, specification sheets, and other documentation should be readily accessible for reference.

#### 5.4 Dynamic Testing

#### 5.4.1 Key Testing Considerations

- Test conditions: test conditions should include not only "normal" or "expected" values, but also stress conditions (such as a high number of users accessing a network at the same time). Test conditions should extend to boundary values, unexpected data entries, error conditions, reasonableness challenges (e.g., empty fields, and date outliers), branches, data flow, and combinations of inputs.
- Simulation tests: some testing may be performed using simulators, usually conducted off-line outside of the actual user's computing environment.
- Live, user-site tests: these tests are performed in the end user's computing environment under actual operating conditions. Testing should cover
- continuous operations for a sufficient time to allow the system to encounter a
  wide spectrum of conditions and events in an effort to detect any latent faults that
  are not apparent during normal activities.

#### 5.4.2 Software testing should include:

- Structural testing: this testing takes into account the internal mechanism (structure) of a system or component. It is sometimes referred to as "white box" testing. Structural testing should show that the software creator followed contemporary quality standards (e.g., consensus standards from national and international standards development organizations, such as those listed in Appendix A of this guidance). This testing usually includes inspection (or walk-throughs) of the program code and development documents.
- Functional testing: this testing involves running the program under known
  conditions with defined inputs, and documented outcomes that can be
  compared to pre-defined expectations. Functional testing is sometimes called
  "black box" testing.
- Program build testing: this testing is performed on units of code (modules), integrated units of code, and the program as a whole.
- 134 5.4.3 How test results should be expressed.
- Quantifiable test results should be recorded in quantified rather than qualified (e.g., pass/fail) terms. Quantified results allow for subsequent review and independent evaluation of the test results.

#### 5.5 Static Verification Techniques

While dynamic testing is an important part of validation, we believe that by using dynamic testing alone it would be virtually impossible to fully demonstrate complete and correct system performance. A conclusion that a system is validated is also supported by numerous verification steps undertaken throughout the system development. These include static analyses such as document and code inspections, walk-throughs, and technical reviews. Where available, knowledge of these activities and their outcomes can help to focus testing efforts, and help to reduce the amount of system level functional testing needed at the user site in order to validate that the software meets the user's needs and intended uses.

#### 5.6 Extent of Validation

- When you determine the appropriate extent of system validation, the factors you should consider include (but are not limited to) the following:
- The risk that the system poses to product safety, efficacy, and quality; note that

  product means the FDA regulated article (food, human or veterinary drug,

  biological product, medical device, or radiological product);
  - The risk that the system poses to data integrity, authenticity, and confidentiality;
     and,
    - The system's complexity; a more complex system might warrant a more comprehensive validation effort.

#### 5.7 Independence of Review

It is a quality assurance tenet that objective self-evaluation is difficult. Therefore, where possible, and especially for higher risk applications, computer system validation should be performed by persons other than those responsible for building the system. Two approaches to ensuring an objective review are: (1) Engaging a third party; and, (2) dividing the work within an organization such that people who review the system (or a portion of the system) are not the same people who built it.

#### 5.8 Change Control (Configuration Management)

Systems should be in place to control changes and evaluate the extent of revalidation that the changes would necessitate. The extent of revalidation will depend upon the change's nature, scope, and potential impact on a validated system and established operating conditions.

Changes that cause the system to operate outside of previously validated operating limits would be particularly significant.

Contractor or vendor upgrades or maintenance activities, especially when performed remotely (i.e., over a network), should be carefully monitored because they can introduce changes that might otherwise go unnoticed and have an adverse effect on a validated system. Examples of such activities include installation of circuit boards that might hold new versions of "firmware" software, addition of new network elements, and software "upgrades", "fixes" or "service packs." It is important that system users be aware of such

changes to their system. You should arrange for service providers to advise you regarding the nature of such revisions so you can assess the changes and perform appropriate revalidation.

We consider regression analysis to be an extremely important tool that should be used to assess portions of a system that were themselves unchanged but are nonetheless vulnerable to performance/reliability losses that the changes can cause. For instance, new software might alter performance of other software on a system (e.g., by putting into place new device drivers or other code that programs share.) Regression testing should be performed based on the results of the regression analysis.

#### 6. Special Considerations

#### 6.1 Commercial, Off-The-Shelf Software

Commercial software used in electronic recordkeeping systems subject to part 11 needs to be validated, just as programs written by end users need to be validated. See 62 Federal Register 13430 at 13444-13445 (March 20, 1997.) We do not consider commercial marketing alone to be sufficient proof of a program's performance suitability. The end user is responsible for a program's suitability as used in the regulatory environment. However, the end user's validation approach for off-the-shelf software is somewhat different from what the developer does because the source code and development documentation are not usually available to the end user. End users should validate any program macros and

191	other customizations that they prepare. End users should also be able to validate off-the-shelf
192	software by performing all of the following:

#### 6.1.1 End User Requirements Specifications

End users should document their requirements specifications relative to part 11 requirements and other factors, as discussed above. The end user's requirements specifications may be different from the developer's specifications. If possible, the end user should obtain a copy of the developer's requirements specifications for comparison.

#### 6.1.2 Software Structural Integrity

- Where source code is not available for examination, end users should infer the adequacy of software structural integrity by doing all of the following:
  - Conducting research into the program's use history. This research should include: (1) Identifying known program limitations; (2) evaluating other end user experiences; and, (3) identifying known software problems and their resolution; and
  - Evaluating the supplier's software development activities to determine its
    conformance to contemporary standards. The evaluation should preferably be derived
    from a reliable audit of the software developer, performed by the end
    user's organization or a trusted and competent third party.

#### 6.1.3 Functional Testing of Software

End users should conduct functional testing of software that covers all functions of the program that the end user will use. Testing considerations discussed above should be applied. When the end user cannot directly review the program source code or development documentation (e.g., for most commercial off-the-shelf software, and for some contracted software,) more extensive functional testing might be warranted than when such documentation is available to the user. More extensive functional testing might also be warranted where general experience with a program is limited, or the software performance is highly significant to data/record integrity and authenticity. Note, however, we do not believe that functional testing alone is sufficient to establish software adequacy.

#### 6.2 The Internet

We recognize the expanding role of the Internet in electronic recordkeeping in the context of part 11. Vital records, such as clinical data reports or batch release approvals, can be transmitted from source to destination computing systems by way of the Internet.

#### 6.2.1 Internet Validation

We recognize that the Internet, as computer system, cannot be validated because its configuration is dynamic. For example, when a record is transmitted from source to destination computers, various portions (or packets) of the record may travel along different

paths, a route that neither sender nor recipient can define or know ahead of time. In addition, entirely different paths might be used for subsequent transfers.

The Internet can nonetheless be a trustworthy and reliable communications pipeline for electronic records when there are measures in place to ensure the accurate, complete and timely transfer of data and records from source to destination computing systems.

Validation of both the source and destination computing systems (i.e., both ends of the Internet communications pipeline) should extend to those measures. We therefore consider it extremely important that those measures are fully documented as part of the system requirements specifications, so they can be validated. Examples of such measures include:

- Use of digital signature technology to verify that electronic records have not been altered and that the sender's authenticity is affirmed.
- Delivery acknowledgements such as receipts or separate confirmations executed apart from the Internet (e.g., via fax or voice telephone lines.)

#### **Appendix A - References**

Much has been written about activities that support computer systems validation. You may find the following references useful to your validation efforts.

#### **Food and Drug Administration References**

Electronic Records; Electronic Signatures Final Rule, 62 Federal Register 13430 (March 20, 1997).

Glossary of Computerized System and Software Development Terminology, Division of Field Investigations, Office of Regional Operations, Office of Regulatory Affairs, Food and Drug Administration, August 1995.

Guidance for Industry: Computerized Systems Used in Clinical Trials, Food and Drug Administration, April 1999.

Guidance for Industry and for FDA Staff: General Principles of Software Validation, Center for Devices and Radiological Health, Food and Drug Administration, Draft - June 1997.

Guidance for the Content of Pre-market Submissions for Software Contained in Medical Devices, Office of Device Evaluation, Center for Devices and Radiological Health, Food and Drug Administration, May 1998.

Guidance for Industry, FDA Reviewers and Compliance on Off-the-Shelf Software Use in Medical Devices, Office of Device Evaluation, Center for Devices and Radiological Health, Food and Drug Administration, September 1999.

Guideline on General Principles of Process Validation, Center for Drugs and Biologics, & Center For Devices and Radiological Health, Food and Drug Administration, May 1987.

Reviewer Guidance for a Pre-Market Notification Submission for Blood Establishment Computer Software, Center for Biologics Evaluation and Research, Food and Drug Administration, January 1997

Student Manual 1, Course INV545, Computer System Validation, Division of Human Resource Development, Office of Regulatory Affairs, Food and Drug Administration, 1997.

Technical Report, Software Development Activities, Division of Field Investigations, Office of Regional Operations, Office of Regulatory Affairs, Food and Drug Administration, July 1987.

#### **Other Government References**

W. Richards Adrion, Martha A. Branstad, John C. Cherniavsky. *NBS Special Publication 500-75, Validation, Verification, and Testing of Computer Software*, Center for Programming Science and Technology, Institute for Computer Sciences and Technology, National Bureau of Standards, U.S. Department of Commerce, February 1981.

Martha A. Branstad, John C Cherniavsky, W. Richards Adrion, *NBS Special Publication 500-56, Validation, Verification, and Testing for the Individual Programmer*, Center for Programming Science and Technology, Institute for Computer Sciences and Technology, National Bureau of Standards, U.S. Department of Commerce, February 1980.

J.L. Bryant, N.P. Wilburn, *Handbook of Software Quality Assurance Techniques Applicable to the Nuclear Industry,* NUREG/CR-4640, U.S. Nuclear Regulatory Commission, 1987.

H. Hecht, et.al., *Verification and Validation Guidelines for High Integrity Systems.* NUREG/CR-6293. Prepared for U.S. Nuclear Regulatory Commission, 1995.

Patricia B. Powell, Editor. *NBS Special Publication 500-98, Planning for Software Validation, Verification, and Testing*, Center for Programming Science and Technology, Institute for Computer Sciences and Technology, National Bureau of Standards, U.S. Department of Commerce, November 1982.

Patricia B. Powell, Editor. *NBS Special Publication 500-93, Software Validation, Verification, and Testing Technique and Tool Reference Guide,* Center for Programming Science and Technology, Institute for Computer Sciences and Technology, National Bureau of Standards, U.S. Department of Commerce, September 1982.

Delores R. Wallace, Roger U. Fujii, NIST Special Publication 500-165, Software Verification and Validation: Its Role in Computer Assurance and Its Relationship with Software Project Management Standards, National Computer Systems Laboratory, National Institute of Standards and Technology, U.S. Department of Commerce, September 1995.

Delores R. Wallace, et.al. *NIST Special Publication 500-234, Reference Information for the Software Verification and Validation Process.* Computer Systems Laboratory, National Institute of Standards and Technology, U.S. Department of Commerce, March 1996.

Delores R. Wallace, Editor. *NIST Special Publication 500-235, Structured Testing: A Testing Methodology Using the Cyclomatic Complexity Metric.* Computer Systems Laboratory, National Institute of Standards and Technology, U.S. Department of Commerce, August 1996.

#### **International and National Consensus Standards**

ANSI / ANS-10.4-1987, Guidelines for the Verification and Validation of Scientific and Engineering Computer Programs for the Nuclear Industry, American National Standards Institute, 1987.

IEEE Std 1012-1986, *Software Verification and Validation Plans*, Institute for Electrical and Electronics Engineers, 1986.

*IEEE Standards Collection, Software Engineering*, Institute of Electrical and Electronics Engineers, Inc., 1994. ISBN 1-55937-442-X.

ISO 9000-3:1997, Quality management and quality assurance standards - Part 3: Guidelines for the application of ISO 9001:1994 to the development, supply, installation and maintenance of computer software. International Organization for Standardization, 1997.

ISO/IEC 12119:1994, *Information technology - Software packages - Quality requirements and testing,* Joint Technical Committee ISO/IEC JTC 1, International Organization for Standardization and International Electrotechnical Commission, 1994.

ISO/IEC 12207:1995, *Information technology- Software life cycle processes*, Joint Technical Committee ISO/IEC JTC 1, Subcommittee SC 7, International Organization for Standardization and International Electrotechnical Commission, 1995.

ISO/IEC 14598:1999, *Information technology- Software product evaluation*, Joint Technical Committee ISO/IEC JTC 1, Subcommittee SC 7, International Organization for Standardization and International Electrotechnical Commission, 1999.

Software Considerations in Airborne Systems and Equipment Certification. Special Committee 167 of RTCA. RTCA Inc., Washington, D.C. Tel: 202-833-9339. Document No. RTCA/DO-178B, December 1992.

#### **Production Process Software References**

The Application of the Principles of GLP to Computerized Systems, Environmental Monograph #116, Organization for Economic Cooperation and Development (OECD), 1995.

George J. Grigonis, Jr., Edward J. Subak, Jr., and Michael Wyrick, "Validation Key Practices for Computer Systems Used in Regulated Operations," *Pharmaceutical Technology*, June 1997.

Guide to Inspection of Computerized Systems in Drug Processing, Reference Materials and Training Aids for Investigators, Division of Drug Quality Compliance, Associate Director for Compliance, Office of Drugs, National Center for Drugs and Biologics, & Division of

Field Investigations, Associate Director for Field Support, Executive Director of Regional Operations, Food and Drug Administration, February 1983.

Daniel P. Olivier, "Validating Process Software", FDA Investigator Course: Medical Device Process Validation, Food and Drug Administration.

GAMP Guide For Validation of Automated Systems in Pharmaceutical Manufacture, Version V3.0, Good Automated Manufacturing Practice (GAMP) Forum, March 1998:

Volume 1, Part 1: User Guide
Part 2: Supplier Guide

Volume 2: Best Practice for User and Suppliers.

Technical Report No. 18, Validation of Computer-Related Systems. PDA Committee on Validation of Computer-Related Systems. PDA Journal of Pharmaceutical Science and Technology, Volume 49, Number 1, January-February 1995 Supplement.

Validation Compliance Annual 1995, International Validation Forum, Inc.

#### **General Software Quality References**

Boris Beizer, Black Box Testing, Techniques for Functional Testing of Software and Systems, John Wiley & Sons, 1995. ISBN 0-471-12094-4.

Boris Beizer, Software System Testing and Quality Assurance, International Thomson Computer Press, 1996. ISBN 1-85032-821-8.

Boris Beizer, Software Testing Techniques, Second Edition, Van Nostrand Reinhold, 1990. ISBN 0-442-20672-0.

Richard Bender, *Writing Testable Requirements,* Version 1.0, Bender & Associates, Inc., Larkspur, CA 94777, 1996.

Silvana Castano, et.al., *Database Security*, ACM Press, Addison-Wesley Publishing Company, 1995. ISBN 0-201-59375-0.

Computerized Data Systems for Nonclinical Safety Assessment, Current Concepts and Quality Assurance, Drug Information Association, Maple Glen, PA, September 1988.

M. S. Deutsch, *Software Verification and Validation*, Realistic Project Approaches, Prentice Hall, 1982.

Robert H. Dunn and Richard S. Ullman, *TQM for Computer Software*, Second Edition, McGraw-Hill, Inc., 1994. ISBN 0-07-018314-7.

Elfriede Dustin, Jeff Rashka, and John Paul, Automated Software Testing - Introduction, Management and Performance, Addison Wesley Longman, Inc., 1999. ISBN 0-201-43287-0.

Robert G. Ebenau, and Susan H. Strauss, *Software Inspection Process*, McGraw-Hill, 1994. ISBN 0-07-062166-7.

Richard E. Fairley, *Software Engineering Concepts,* McGraw-Hill Publishing Company, 1985. ISBN 0-07-019902-7.

Michael A. Friedman and Jeffrey M. Voas, Software Assessment - Reliability, Safety, Testability, Wiley-Interscience, John Wiley & Sons Inc., 1995. ISBN 0-471-01009-X.

Tom Gilb, Dorothy Graham, *Software Inspection*, Addison-Wesley Publishing Company, 1993. ISBN 0-201-63181-4.

Robert B. Grady, *Practical Software Metrics for Project Management and Process Improvement*, PTR Prentice-Hall Inc., 1992. ISBN 0-13-720384-5.

Janis V. Halvorsen, A Software Requirements Specification Document Model for the Medical Device Industry, Proceedings IEEE SOUTH EASTCON '93, Banking on Technology, April 4th -7th, 1993, Charlotte, North Carolina.

Bill Hetzel, *The Complete Guide to Software Testing,* Second Edition, A Wiley-QED Publication, John Wiley & Sons, Inc., 1988. ISBN 0-471-56567-9.

Watts S. Humphrey, *A Discipline for Software Engineering*. Addison-Wesley Longman, 1995. ISBN 0-201-54610-8.

Watts S. Humphrey, *Managing the Software Process*, Addison-Wesley Publishing Company, 1989. ISBN 0-201-18095-2.

Capers Jones, Software Quality, Analysis and Guidelines for Success, International Thomson Computer Press, 1997. ISBN 1-85032-867-6.

Stephen H. Kan, *Metrics and Models in Software Quality Engineering,* Addison-Wesley Publishing Company, 1995. ISBN 0-201-63339-6.

Cem Kaner, Jack Falk, Hung Quoc Nguyen, *Testing Computer Software*, Second Edition, Vsn Nostrand Reinhold, 1993. ISBN 0-442-01361-2.

Craig Kaplan, Ralph Clark, Victor Tang, Secrets of Software Quality, 40 Innovations from IBM, McGraw-Hill, 1995. ISBN 0-07-911795-3.

Edward Kit, Software Testing in the Real World, Addison-Wesley Longman, 1995, ISBN 0-

201-87756-2.

Alan Kusinitz, "Software Validation"; Current Issues in Medical Device Quality Systems, Association for the Advancement of Medical Instrumentation, 1997. ISBN 1-57020-075-0.

Michael R. Lyu, Editor, *Handbook of Software Reliability Engineering,* IEEE Computer Society Press, McGraw-Hill, 1996. ISBN 0-07-039400-8.

Steven R. Mallory, Software Development and Quality Assurance for the Healthcare Manufacturing Industries, Interpharm Press, Inc., 1994. ISBN 0-935184-58-9.

Brian Marick, *The Craft of Software Testing*, Prentice Hall PTR, 1995. ISBN 0-13-177411-5.

Glenford J. Myers, *The Art of Software Testing*, John Wiley & Sons, 1979. ISBN 0-471-04328-1.

Daniel Olivier, Conducting Software Audits, Auditing Software for Conformance to FDA Requirements, Computer Application Specialists, San Diego, CA, 1994.

William Perry, Effective Methods for Software Testing, John Wiley & Sons, Inc. 1995. ISBN 0-471-06097-6.

William E. Perry, Randall W. Rice, *Surviving the Top Ten Challenges of Software Testing*, Dorset House Publishing, 1997. ISBN 0-932633-38-2.

Roger S. Pressman, *Software Engineering, A Practitioner's Approach*, Third Edition, McGraw-Hill Inc., 1992. ISBN 0-07-050814-3.

Roger S. Pressman, A Manager's Guide to Software Engineering, McGraw-Hill Inc., 1993 ISBN 0-07-050820-8.

A. P. Sage, J. D. Palmer, Software Systems Engineering, John Wiley & Sons, 1990.

Joc Sanders, Eugene Curran, *Software Quality*, Addison-Wesley Publishing Co., 1994. ISBN 0-201-63198-9.

Ken Shumate, Marilyn Keller, Software Specification and Design, A Disciplined Approach for Real-Time Systems, John Wiley & Sons, 1992. ISBN 0-471-53296-7.

Dennis D. Smith, *Designing Maintainable Software*, Springer-Verlag, 1999. ISBN 0-387-98783-5.

lan Sommerville, *Software Engineering,* Third Edition, Addison Wesley Publishing Co., 1989. ISBN 0-201-17568-1.

Karl E. Wiegers, *Creating a Software Engineering Culture*, Dorset House Publishing, 1996. ISBN 0-932633-33-1.

Karl E. Wiegers, *Software Inspection, Improving Quality with Software Inspections*, Software Development, April 1995, pages 55-64.

Karl E. Wiegers, Software Requirements, Microsoft Press, 1999. ISBN 0-7356-0631-5.

DocID Validation Draft.PostRES.doc 08/29/01